Aim of this study is to investigate the effects of a panel of PI3K isoform inhibitors in Ph+ B-ALL cell lines by combining their anti-tumor activity with anti Bcr-Abl drugs. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.